Posted by Michael Wonder on 14 Jun 2025
GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the EMA to expand use in adults 18 years and older
13 June 2025 - Regulatory decision anticipated H1, 2026.
GSK today announced that the EMA has accepted the company’s regulatory application to expand the use of its adjuvanted recombinant respiratory syncytial virus vaccine to include adults from 18 years of age.
